# Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

> **NCT06605586** · PHASE1,PHASE2 · RECRUITING · sponsor: **Stichting Hemato-Oncologie voor Volwassenen Nederland** · enrollment: 20 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Tasquinimod

## Key facts

- **NCT ID:** NCT06605586
- **Lead sponsor:** Stichting Hemato-Oncologie voor Volwassenen Nederland
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2027-12
- **Final completion:** 2030-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06605586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06605586, "Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06605586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*